丹麦1986-2020年口咽癌发病率与结局:一项基于人群的DAHANCA研究
该研究基于丹麦全国DAHANCA数据库和健康登记,纳入1986-2020年8499例口咽鳞癌患者,分析发病率和生存趋势。结果显示粗发病率从1.4升至7.7,HPV相关比例从30%升至69%,5年OS从31%升至66%,治疗强化使调整后5年OS改善29%(HR 0.22,95%CI 0.15-0.33),与HPV状态无关。
要点
- 丹麦口咽鳞癌粗发病率从1.4升至7.7,HPV相关比例从30%升至69%。
- 治疗强化使调整后5年OS改善29%(HR 0.22,95%CI 0.15-0.33)。
- 生存改善与HPV状态无关,归因于全国性治疗强化策略。
核心结论
- 丹麦是HPV相关口咽鳞癌高发地区,35年间生存改善主要归因于全国实施的治疗强化策略,且获益与HPV状态无关。
研究设计与样本
- 基于丹麦头颈癌协作组(DAHANCA)数据库和国家健康登记的前瞻性收集、全国性人群队列研究,纳入1986-2020年确诊的8499例口咽鳞癌患者。
主要发现
- 总粗发病率从1.4升至7.7(男性2.1-11.5,女性0.8-3.9),HPV相关比例从30%升至69%。
- 总队列5年OS从31%升至66%,改善35%。
- 治疗强化使调整后5年OS改善29%(HR 0.22,95%CI 0.15-0.33),与HPV状态无关。
关键数值与推荐
- 5年无病生存(DFS)和总生存(OS)采用Cox比例风险模型估计,暴露因素为HPV相关p16表达和基于放疗的治疗强化。
- 混杂和间接效应采用反事实框架评估,校正日历时期、年龄、分期、吸烟和性别。
临床怎么用
- 丹麦全国性治疗强化策略与口咽鳞癌生存改善相关,且获益不依赖于HPV状态,支持在HPV相关高发地区实施强化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The global incidence of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) varies widely. Long-term, population-based studies with consistent treatment protocols are essential for understanding geographic differences in viral impact, treatment response and survival. With this nationwide population-based study, we aimed to examine gender- and age-specific incidence and survival trends in Danish patients with OPSCC from 1986 to 2020, in relation to HPV-status and treatment intensification. METHODS: All Danish patients diagnosed with OPSCC were prospectively collected via the Danish Head and Neck Cancer Group (DAHANCA) database and national health registries. Patients were treated according to prevailing national clinical guidelines. Age-standardized, gender-specific incidence rates were calculated. Five-year disease-free (DFS) and overall survival (OS) were estimated using Cox proportional hazards models with HPV-related p16 expression and radiotherapy-based treatment intensification as exposures. Confounding and indirect effects were assessed using a counterfactual framework adjusted for calendar period, age, stage, smoking and gender. RESULTS: A total of 8499 patients were identified, with a 2.8:1 male:female ratio. Overall crude incidence increased from 1.4 to 7.7 (men:2.1-11.5, women:0.8-3.9) in parallel with an increasement in HPV-relation from 30% to 69%. Five-year OS improved by 35% in the total cohort (from 31% to 66%), and treatment intensification resulted in improved adjusted 5-year OS by 29% (HR 0.22, 95% CI, 0.15-0.33), irrespective of HPV-status. CONCLUSIONS: Denmark is a high-incidence area for HPV-related OPSCC. Improved survival over the 35-year period is largely attributable to nationally implemented intensified treatment strategies, with benefits observed regardless of HPV-status.
引用
- Lassen P, Alsner J, Kristensen CA, et al. Incidence and outcome of oropharynx carcinoma in Denmark 1986-2020: A population based DAHANCA study. Eur J Cancer. 2026. PMID: 42019225. doi:10.1016/j.ejca.2026.116748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。